Home Companies Pulmovant COMPANY
Status: Acquired, now part of Roivant Sciences · How status works
Clinical Phase 3
11 open jobs · last seen Oct 23, 2026 · 5 sources
Keywords: respiratory pulmonary hypertension interstitial lung disease Vascular Diseases Cardiovascular Diseases Fibrosis Lung Diseases Show all 7 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Manager, CMC Quality, Pulmovant Remote, US Oct 20, 2026 Oct 21, 2026 Head of Analytical Development, Pulmovant Remote, US Oct 14, 2026 Oct 15, 2026 Associate Director, Drug Product, Pulmovant Remote, US Oct 14, 2026 Oct 15, 2026 Senior Manager / Associate Director, CMC Project Management, Pulmovant Remote Oct 9, 2026 Oct 10, 2026 Executive Assistant, Pulmovant Remote, US Oct 9, 2026 Oct 9, 2026
See all 11 jobs
At a glance HQ Waltham, MA source Stage Clinical Phase 3 Latest trial 3: A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) (Aug 31, 2026) source Trial and FDA signals New trial + clinical hiring Started a Phase 3 trial (NCT07816185, actual start Aug 31, 2026); since then posted 5 clinical-operations roles. ClinicalTrials.gov NCT07816185 (Aug 31, 2026)Evidence (1 event) Aug 31, 2026 · ClinicalTrials.gov NCT07816185 leadSponsor.name='Pulmovant, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-09-11; briefTitle='A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)' Job counts as of Oct 18, 2026. All trial and FDA signals
Timeline Oct 9, 2026 Board tracked Radar started tracking this company’s job board (11 open jobs at last check). source ↗ Aug 31, 2026 Trial start 3: A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) source ↗ Dec 23, 2025 Trial start Phase 2: A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD source ↗ Jun 10, 2025 Trial start 1: A Phase 1 Study of Mosliciguat in Healthy, Adult Males source ↗ Oct 29, 2024 Trial start Phase 2: A Study of Mosliciguat in PH-ILD source ↗ Upcoming milestones 2026-12 (ESTIMATED) · Phase 2 · A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD · NCT07333183 Jan 28, 2029 (ESTIMATED) · 3 · A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) · NCT07816185 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 11 Title Location (from posting, not HQ) Employer posted First seen Level Manager, CMC Quality, Pulmovant Remote, US Oct 20, 2026 Oct 21, 2026 Not stated Head of Analytical Development, Pulmovant Remote, US Oct 14, 2026 Oct 15, 2026 Executive Description Associate Director, Drug Product, Pulmovant Remote, US Oct 14, 2026 Oct 15, 2026 Senior Description Senior Manager / Associate Director, CMC Project Management, Pulmovant Remote Oct 9, 2026 Oct 10, 2026 Senior Description Executive Assistant, Pulmovant Remote, US Oct 9, 2026 Oct 9, 2026 Senior Description Manager/Senior Manager, Statistical Programming, Pulmovant Remote, US Sep 28, 2026 Oct 9, 2026 Mid Description Senior Manager, Clinical Supply, Pulmovant Remote, US Sep 25, 2026 Oct 9, 2026 Senior Description Senior Director, Regulatory Affairs, Pulmovant Remote, US Sep 25, 2026 Oct 9, 2026 Senior Description Associate Director, Drug Substance, Pulmovant Remote, US Sep 24, 2026 Oct 9, 2026 Senior Description Director, Biostatistics, Pulmovant Remote, US Sep 23, 2026 Oct 9, 2026 Senior Description Senior Director, Clinical Development, Pulmovant Remote, US Sep 22, 2026 Oct 9, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Clinical trials (lead sponsor) 4 Record Title Phase Status Start Primary completion NCT07816185 A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) 3 Recruiting Aug 31, 2026 Jan 28, 2029 (estimated) NCT06635850 A Study of Mosliciguat in PH-ILD Phase 2 Active, not recruiting Oct 29, 2024 May 26, 2026 (actual) NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD Phase 2 Recruiting Dec 23, 2025 2026-12 (estimated) NCT07185321 A Phase 1 Study of Mosliciguat in Healthy, Adult Males 1 Completed Jun 10, 2025 Jun 30, 2025 (actual)
Connect See your connections at Pulmovant on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18